The University of Virginia Cancer Center is conducting a clinical research study for adults ages 18 and over who have Cutaneous Squamous Cell Carcinoma (CSCC) and have had surgery and radiation therapy. The purpose of this research study is to determine if an immunotherapy drug (cemiplimab) will prevent cutaneous squamous cell cancer from returning after surgery and radiation.
Treatment can last for up to 3 years (this includes 48 weeks in Part 1 and potentially 96 weeks in Part 2), including the screening visit, and the end of treatment visit. After you come off treatment your visits will occur every 4 months for Years 1-2, and every 6 months >/= year 3. Following this, you’ll be contacted by phone every 3 months for survival and cancer treatment status. Any procedures being done above and beyond standard of care will be provided at no cost to you or your insurance.
Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT03969004
Compensation: $50 per completed visit